The 10-second takeaway
For the quarter ended March 31 (Q1), Pacira Pharmaceuticals beat expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share contracted.
Margins increased across the board.
Pacira Pharmaceuticals booked revenue of $7.8 million. The four analysts polled by S&P Capital IQ expected net sales of $7.5 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $3.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.47. The four earnings estimates compiled by S&P Capital IQ forecast -$0.40 per share. GAAP EPS were -$0.47 for Q1 versus -$0.98 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 16.8%, 1,170 basis points better than the prior-year quarter. Operating margin was -142.7%, 4,170 basis points better than the prior-year quarter. Net margin was -152.4%, 10,060 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $8.1 million. On the bottom line, the average EPS estimate is -$0.48.
Next year's average estimate for revenue is $34.7 million. The average EPS estimate is -$1.37.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pacira Pharmaceuticals is buy, with an average price target of $16.20.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Pacira Pharmaceuticals the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Pacira Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.